Aurigene Pharmaceutical Services a subsidiary of Dr. Reddy's Laboratories plans to invest US$40 million to construct new state-of-the art development and manufacturing facility in Hyderabad.
The construction of a state-of-the-art development and manufacturing facility is underway, and it is specifically designed for the production of therapeutic proteins, antibodies, and viral vectors.
The facility is built upon a cutting-edge design concept, which allows for maximum flexibility in terms of accommodating multiple products and platforms. This flexibility is crucial in providing a wide range of services across therapeutic proteins, antibodies, and viral vectors.
In addition, the facility offers exclusive access to an established large-scale GMP (Good Manufacturing Practise) manufacturing facility.
This manufacturing facility has a drug substance capacity of 15,000 litres and fill-finish capabilities, enabling the seamless production of commercial quantities. Furthermore, an additional fill-finish line is currently under construction and is expected to be validated before the end of 2024.
The facility is planned to be fully operational in the first half of 2024, to support the therapeutic protein, antibody, and viral vector development and manufacturing needs.
Aurigene Pharmaceutical Services